Subtopic Deep Dive
Prostate Cancer Genomic Profiling
Research Guide
What is Prostate Cancer Genomic Profiling?
Prostate Cancer Genomic Profiling uses integrative genomic analyses to identify recurrent alterations like PTEN loss, SPOP mutations, and ETS fusions in prostate tumors.
Taylor et al. (2010) performed integrative genomic profiling on 218 prostate cancers, revealing distinct subtypes defined by ETS fusions, SPOP mutations, and PTEN deletions (Cancer Cell, 3731 citations). Tomlins et al. (2005) discovered recurrent TMPRSS2-ETS gene fusions in 23% of prostate cancers using bioinformatics outlier analysis (Science, 3816 citations). Robinson et al. (2015) sequenced 150 metastatic castration-resistant prostate cancers, identifying actionable genomic drivers (Cell, 3556 citations).
Why It Matters
Genomic profiling classifies prostate cancers into subtypes correlating with aggressiveness and therapeutic response, enabling precision medicine. Taylor et al. (2010) showed SPOP-mutant tumors respond differently to androgen deprivation than ETS-fusion positive cases. Robinson et al. (2015) identified therapeutic vulnerabilities like DNA repair defects in advanced cases, guiding PARP inhibitor use. Tomlins et al. (2005) fusions inform biopsy-based risk stratification, reducing overtreatment.
Key Research Challenges
Intratumor Heterogeneity
Prostate tumors exhibit spatial and temporal genomic diversity, complicating single-biopsy profiling. Taylor et al. (2010) noted varying ETS fusion prevalence across tumor regions. Multi-region sequencing is needed but resource-intensive (Robinson et al., 2015).
Actionable Variant Scarcity
Few alterations in profiled genomes directly match approved therapies. Robinson et al. (2015) found only 20% of advanced cases had targetable drivers despite comprehensive sequencing. Bridging genomic findings to clinical trials remains limited.
Subtype Response Prediction
Correlating SPOP/PTEN subtypes with AR-targeted therapy outcomes requires longitudinal data. Taylor et al. (2010) subtypes predict aggressiveness but not uniformly enzalutamide response (Scher et al., 2012).
Essential Papers
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Ian F. Tannock, Ronald de Wit, William R. Berry et al. · 2004 · New England Journal of Medicine · 5.7K citations
When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared wi...
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Philip W. Kantoff, Celestia S. Higano, Neal D. Shore et al. · 2010 · New England Journal of Medicine · 5.4K citations
The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer. No effect on the time to disease progression was observed. (Funded by Dendreon; Cl...
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad et al. · 2012 · New England Journal of Medicine · 4.5K citations
Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy. (Funded by Medivation and Astellas Pharma Global Development; AFFIR...
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
Anthony V. D’Amico · 1998 · JAMA · 4.5K citations
Low-risk patients had estimates of 5-year PSA outcome after treatment with RP, RT, or implant with or without neoadjuvant androgen deprivation that were not statistically different, whereas interme...
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono, Christopher J. Logothetis, Arturo Molina et al. · 2011 · New England Journal of Medicine · 4.3K citations
The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. (...
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schröder, Jonas Hugosson, Monique J. Roobol et al. · 2009 · New England Journal of Medicine · 4.0K citations
PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis. (Current Controlled Trials number, ISRCTN49127736.)
Recurrent Fusion of <i>TMPRSS2</i> and ETS Transcription Factor Genes in Prostate Cancer
Scott A. Tomlins, Daniel R. Rhodes, Sven Perner et al. · 2005 · Science · 3.8K citations
Recurrent chromosomal rearrangements have not been well characterized in common carcinomas. We used a bioinformatics approach to discover candidate oncogenic chromosomal aberrations on the basis of...
Reading Guide
Foundational Papers
Start with Tomlins et al. (2005) for ETS fusion discovery mechanism; then Taylor et al. (2010) for comprehensive subtype framework across 218 primary tumors.
Recent Advances
Study Robinson et al. (2015) for advanced metastatic profiling and therapeutic implications.
Core Methods
Outlier gene expression for rearrangements (Tomlins 2005); integrative exome/copy number/RNA-seq (Taylor 2010); clinical-grade sequencing panels (Robinson 2015).
How PapersFlow Helps You Research Prostate Cancer Genomic Profiling
Discover & Search
Research Agent uses searchPapers('prostate cancer ETS fusions PTEN SPOP') to retrieve Tomlins et al. (2005), citationGraph to map 3816 downstream citations, findSimilarPapers on Taylor et al. (2010) for 3731-cited subtype papers, and exaSearch for unpublished preprints on Robinson et al. (2015) extensions.
Analyze & Verify
Analysis Agent applies readPaperContent on Taylor et al. (2010) to extract subtype frequencies, verifyResponse with CoVe against Tomlins et al. (2005) fusion data, and runPythonAnalysis to plot PTEN deletion rates across 218 samples using pandas; GRADE grading scores evidence strength for SPOP-therapy correlations.
Synthesize & Write
Synthesis Agent detects gaps in SPOP subtype treatment data via contradiction flagging across Scher et al. (2012) and Robinson et al. (2015), Writing Agent uses latexEditText for review drafting, latexSyncCitations to link Tomlins et al. (2005), and latexCompile for submission-ready PDF; exportMermaid visualizes genomic subtype trees.
Use Cases
"Compute survival correlation of PTEN loss vs ETS fusions in profiled cohorts"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas survival curves from Taylor 2010 + Robinson 2015 data) → matplotlib plot of hazard ratios.
"Draft LaTeX review on SPOP mutations in prostate cancer subtypes"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro) → latexSyncCitations (Tomlins 2005, Taylor 2010) → latexCompile → PDF with integrated figures.
"Find code for TMPRSS2-ETS fusion detection pipelines"
Research Agent → paperExtractUrls (Tomlins 2005) → Code Discovery → paperFindGithubRepo → githubRepoInspect → validated fusion caller scripts.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ ETS/PTEN papers: searchPapers → citationGraph → GRADE all → structured subtype report. DeepScan applies 7-step analysis to Robinson et al. (2015): readPaperContent → CoVe verify → runPythonAnalysis on driver frequencies → checkpoint critique. Theorizer generates hypotheses linking SPOP mutations to enzalutamide resistance from Scher et al. (2012) + Taylor et al. (2010).
Frequently Asked Questions
What is Prostate Cancer Genomic Profiling?
It identifies recurrent alterations like TMPRSS2-ETS fusions (Tomlins et al., 2005), SPOP mutations, and PTEN loss (Taylor et al., 2010) via integrative sequencing to define molecular subtypes.
What methods are used?
Bioinformatics outlier analysis detects fusions (Tomlins et al., 2005); whole-exome/genome sequencing with copy number analysis defines subtypes (Taylor et al., 2010; Robinson et al., 2015).
What are key papers?
Tomlins et al. (2005, Science, 3816 citations) discovered ETS fusions; Taylor et al. (2010, Cancer Cell, 3731 citations) profiled 218 tumors; Robinson et al. (2015, Cell, 3556 citations) analyzed metastatic cases.
What open problems exist?
Intratumor heterogeneity limits biopsy accuracy (Taylor et al., 2010); few actionable targets in advanced disease (Robinson et al., 2015); subtype-specific therapy predictors lacking.
Research Prostate Cancer Treatment and Research with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Prostate Cancer Genomic Profiling with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.